WallStSmart

Becton Dickinson and Company (BDX)vsInnovative Eyewear Inc. (LUCY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 916264% more annual revenue ($21.92B vs $2.39M). BDX leads profitability with a 8.0% profit margin vs 0.0%. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

LUCY

Hold

38

out of 100

Grade: F

Growth: 4.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.9%)

Margin of Safety

+36.9%

Fair Value

$286.42

Current Price

$158.27

$128.15 discount

UndervaluedFair: $286.42Overvalued

Intrinsic value data unavailable for LUCY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$56.49B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

LUCY2 strengths · Avg: 9.0/10
Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$3.07B8/10

Generating 3.1B in free cash flow

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.5x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

LUCY4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.89M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : LUCY

The strongest argument for LUCY centers on Price/Book, Free Cash Flow.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : LUCY

The primary concerns for LUCY are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

LUCY carries more volatility with a beta of 3.23 — expect wider price swings.

LUCY is growing revenue faster at 1.6% — sustainability is the question.

LUCY generates stronger free cash flow (3.1B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Innovative Eyewear Inc.

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Innovative Eyewear Inc. (LUCY) is at the forefront of the smart eyewear market, combining cutting-edge technology with contemporary design to serve a tech-oriented consumer base. The company's flagship Lucyd product line integrates audio capabilities and seamless connectivity, offering practical functionality while maintaining fashionable appeal. With an unwavering commitment to innovation and user experience enhancement, LUCY is poised to capitalize on the expanding demand for multifunctional wearables, positioning itself for substantial growth in the dynamic eyewear industry.

Want to dig deeper into these stocks?